[Form 3] Avalo Therapeutics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) director Kevin Robert Lind filed an initial Form 3 reporting that he does not beneficially own any securities of the issuer. The Form 3 lists the qualifying event date as 10/01/2025 and is signed by Donald R. Reynolds by power of attorney on 10/02/2025. The filing gives the reporter's address as 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Donald R. Reynolds, by Power of Attorney	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kevin Robert Lind report on the Form 3 for AVTX?

The Form 3 states that Kevin Robert Lind does not beneficially own any securities of Avalo Therapeutics as of the event date 10/01/2025.

When was the Form 3 event date and who signed the filing?

The event date is 10/01/2025 and the Form 3 was signed by Donald R. Reynolds by power of attorney on 10/02/2025.

What is the reporting person's relationship to Avalo Therapeutics (AVTX)?

The filing indicates the reporting person is a Director of Avalo Therapeutics.

Does the Form 3 disclose any derivative or non-derivative holdings?

No. The Form 3 explicitly states: "No securities are beneficially owned."

What address is listed for the reporting person on the Form 3?

The address listed is 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.